You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 7,935,718

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,935,718

Title:	Treatment of dyskinesia
Abstract:	The present invention relates to the use of compounds that enhance H.sub.3-histamine receptor activity, or activation (e.g. H.sub.3-histamine receptor agonists) for the treatment of dyskinesia. The compounds are particularly useful for treating dyskinesia associated with parkinsonian therapy.
Inventor(s):	Brotchie; Jonathan (Manchester, GB), Hill; Michael (Oldham, GB), Crossman; Alan (Manchester, GB)
Assignee:	Motac Neuroscience Limited (Manchester, GB)
Application Number:	10/974,980
Patent Claims:	1. A method of treating dyskinesia associated with dopamine replacement therapy comprising administering to a subject in need of such treatment a selective H.sub.3-histamine receptor agonist, wherein the selective H3-histamine receptor agonist enhances H.sub.3-histamine receptor activity or activation to a greater extent than the activity of other types of histamine receptors, thus treating dyskinesia associated with dopamine replacement therapy. 2. The method according to claim 1 wherein the H.sub.3-histamine receptor agonist is selected from the group consisting of imetit, imepip and R(-)-alpha-methylhistamine. 3. The method according to claim 1 wherein said dyskinesia is associated with movement disorders. 4. The method according to claim 3 wherein said dyskinesia is associated with parkinsonism. 5. The method according to claim 4 wherein the parkinsonism is idiopathic Parkinson's disease or post-encephalitic parkinsonism. 6. The method according to claim 4 wherein the parkinsonism results from head injury, the treatment of schizophrenia, drug intoxication or manganese poisoning. 7. The method according to claim 1 wherein said dyskinesia is associated with Huntington's disease, idiopathic torsion dystonia, tardive dyskinesia or off-dystonia in Parkinson's disease. 8. The method according to claims 1 wherein said dyskinesia is a side-effect of a therapeutic agent. 9. The method according to claim 8 wherein said dyskinesia is associated with agents used to treat movement disorders. 10. The method according to claim 8 wherein the agent is L-DOPA, Chloro-APB or apomorphine. 11. The method according to claim 8 wherein the agent is used to treat parkinsonism. 12. The method according to claim 1 wherein said treatment is prophylactic treatment of dyskinesia. 13. The method according to claim 1 wherein said dyskinesia is associated with movement disorders and said H.sub.3-histamine receptor agonist is imetit, imepip or R(-)-alpha-methylhistamine. 14. A combination therapeutic method of treating dyskinesia associated with dopamine replacement therapy comprising administering to a subject in need of such treatment a selective H.sub.3-histamine receptor agonist, wherein the selective H.sub.3-histamine receptor agonist enhances H.sub.3-histamine receptor activity or activation to a greater extent than the activity of other types of histamine receptors, wherein the selective H.sub.3-histamine receptor agonist is administered in combination with other compounds or treatments that reduce dyskinesia, thus treating dyskinesia associated with dopamine replacement therapy. 15. The method according to claim 14 wherein said other compounds comprise NMDA receptor-antagonists. 16. The method of claim 1, wherein the dopamine replacement therapy is for Parkinsonism or another basal ganglia-related movement disorder. 17. The method according to claim 1, wherein the dopamine replacement therapy comprises administration of L-DOPA or apomorphine. 18. The method according to claim 1, wherein the dyskinesia is L-DOPA-induced dyskinesia. 19. The method according to claim 1, wherein the dyskinesia is apomorphine-induced dyskinesia. 20. The method of claim 14, wherein the dopamine replacement therapy is for Parkinsonism or another basal ganglia-related movement disorder. 21. The method according to claim 14, wherein the dopamine replacement therapy comprises administration of L-DOPA or apomorphine. 22. The method according to claim 14, wherein the dyskinesia is L-DOPA-induced dyskinesia. 23. The method according to claim 14, wherein the dyskinesia is apomorphine-induced dyskinesia.

Details for Patent 7,935,718

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924	⤷ Try a Trial	2022-05-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.